$2.64
6.05% yesterday
Nasdaq, Nov 25, 10:04 pm CET
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Inozyme Pharma Inc Stock price

$2.64
-2.15 44.89% 1M
-1.93 42.23% 6M
-1.62 38.03% YTD
-1.08 29.03% 1Y
-5.95 69.27% 3Y
-14.90 84.95% 5Y
-14.90 84.95% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.17 6.05%
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Key metrics

Market capitalization $169.59m
Enterprise Value $84.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-99.67m
Free Cash Flow (TTM) Free Cash Flow $-91.36m
Cash position $131.61m
EPS (TTM) EPS $-1.55
P/E forward negative
Short interest 5.44%
Show more

Is Inozyme Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Inozyme Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

Buy
100%

Financial data from Inozyme Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.87 0.87
33% 33%
-
-0.87 -0.87
33% 33%
-
- Selling and Administrative Expenses 20 20
0% 0%
-
- Research and Development Expense 78 78
56% 56%
-
-99 -99
39% 39%
-
- Depreciation and Amortization 0.87 0.87
33% 33%
-
EBIT (Operating Income) EBIT -100 -100
38% 38%
-
Net Profit -96 -96
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inozyme Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inozyme Pharma Inc Stock News

Neutral
GlobeNewsWire
15 days ago
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:
Neutral
GlobeNewsWire
21 days ago
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –
Neutral
GlobeNewsWire
about one month ago
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
More Inozyme Pharma Inc News

Company Profile

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Head office United States
CEO Doug Treco
Employees 59
Founded 2015
Website www.inozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today